Sponsored Satellite Symposia on Sunday, 30th September 2018

18.30–19.30
Future of Genomic Testing in Hematological Malignancies
(Illumina)

Chairs: R. Rosenquist, M. Meggendorfer
Clinical implementation of whole-genome sequencing in hematological
malignancies: are we there yet?
R. Rosenquist, Stockholm, Sweden
Whole genome sequencing and Artifi cial Intelligence –
where are we heading?
M. Meggendorfer, Munich, Germany
18.30–19.30
Accurate and Timely Diagnostic Solutions – A Comparative Study of IHC Systems
(Leica Biosystems Ltd)

Moderator: C. Rhoades, Newcastle, UK
Accurate and Timely Diagnostic Solutions –
A Comparative Study of IHC Systems
C. Rhoades, Newcastle, UK

Sponsored Satellite Symposia on Monday, 1st October 2018

13.30–14.30
CD30: Informing Diagnosis and Treatment in CTCL and PTCL
(Seattle Genetics and Takeda)

13.30–13.35 Welcome and introduction
A. Gru, Virginia, USA
13.35–13.55 CD30 testing: differential diagnoses and decision-making
J. Pawade, Bristol, UK
A. Gru, Virginia, USA
13.55–14.15 A practical guide to CD30 testing in the management of CTCL and PTCL
J. Pawade, Bristol, UK
A. Gru, Virginia, USA
14.15–14.25 Ask the experts: a Q&A session
J. Pawade, Bristol, UK
A. Gru, Virginia, USA
14.25–14.30 Summary and close
J. Pawade, Bristol, UK

 

17.00–18.30
Cell of Origin testing in DLBCL: a new paradigm towards precision medicine
(Celgene)

Moderator: S. Dirnhofer, Switzerland
Clinical experience with CoO stratified trials in DLBCL
G. Nowakowski, USA
GEP tools in CoO testing
C. Burton, UK
Practical implementation of CoO testing in real life
E. Campo, Spain
CoO testing in the WHO 2016 classification and ESMO guidelines:
practical consequences
S. Dirnhofer, Switzerland
Closing
S. Dirnhofer, Switzerland

Sponsored Satellite Symposia on Tuesday, 2nd October 2018

13.30–14.30
Precision Medecine in lymphoid malignancies: transferring scientific insight into clinical practice
(Janssen)

Moderator: K. Stamatopoulos, Thessaloniki, Greece
Introduction
K. Stamatopoulos, Thessaloniki, Greece
The impact of genomics on understanding the pathogenesis
of hematological malignancies
E. Campo, Barcelona, Spain
Genomics in routine diagnostics of hematological malignancies
R. Rosenquist, Stockholm, Sweden
Applying advances in scientifi c understanding in the clinic
K. Stamatopoulos, Thessaloniki, Greece
Panel discussion
All